NEW YORK (GenomeWeb) – MDNA Life Sciences announced today an exclusive licensing agreement with Laboratory Corporation of America for a liquid biopsy-based noninvasive test for patients who may have prostate cancer.

Under the terms of the deal, which covers the US, LabCorp will be able to use MDNA's technology to develop and commercialize a test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
12
Sponsored by
Qiagen

This webinar will discuss ongoing work to apply T-cell receptor sequencing (TCRseq) approaches to immunotherapy monitoring for melanoma patients.